Blocking extracellular activation of myostatin as a strategy for treating muscle wasting

• Published in: Scientific reports Vol. 8; no. 1; pp. 2292 - 15
• Main Authors: Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, M. T., Salta, L., Long, K., McConaughy, W., Capili, A., Boston, C., Carven, G. J., Mahanthappa, N. K., Turner, K. J., Donovan, A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.02.2018; Nature Publishing Group
• Subjects: 13/51; 631/154/51/1568; 631/80/86/2368; 64/60; 692/308/153; 82/1; 82/103; 82/83; Animals; Antibodies, Monoclonal - administration & dosage; Atrophy; Blocking antibodies; Bone Morphogenetic Proteins - antagonists & inhibitors; Extracellular matrix; Growth Differentiation Factors - antagonists & inhibitors; Growth factors; Humanities and Social Sciences; Humans; Immunologic Factors - administration & dosage; Injections, Intraperitoneal; Male; Mice, Inbred C57BL; Monoclonal antibodies; multidisciplinary; Muscles - pathology; Myostatin; Myostatin - antagonists & inhibitors; Proteolysis; Rodents; Sarcopenia - drug therapy; Science; Science (multidisciplinary); Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-20524-9

Many growth factors are intimately bound to the extracellular matrix, with regulated processing and release leading to cellular stimulation. Myostatin and GDF11 are closely related members of the TGFβ family whose activation requires two proteolytic cleavages to release the growth factor from the prodomain. Specific modulation of myostatin and GDF11 activity by targeting growth factor-receptor interactions has traditionally been challenging. Here we demonstrate that a novel strategy for blocking myostatin and GDF11, inhibition of growth factor release, specifically and potently inhibits signaling both in vitro and in vivo . We developed human monoclonal antibodies that selectively bind the myostatin and GDF11 precursor forms, including a subset that inhibit myostatin proteolytic activation and prevent muscle atrophy in vivo . The most potent myostatin activation-blocking antibodies promoted robust muscle growth and resulted in significant gains in muscle performance in healthy mice. Altogether, we show that blocking the extracellular activation of growth factors is a potent method for preventing signaling, serving as proof of concept for a novel therapeutic strategy that can be applied to other members of the TGFβ family of growth factors.